Looking For The New Lantus: Next-Gen Diabetes Hopefuls Defy Risks
This article was originally published in Start Up
The diabetes market presents competitive, commercial, and regulatory challenges, but its size and breadth spur emerging biotechs to develop an ever-wider range of treatments and technologies.
You may also be interested in...
Lilly nabbed multiple molecules for its early-stage diabetes portfolio via a $55m-plus partnership with KeyBioscience, making sure that the big pharma's pipeline continues to add products to its largest franchise.
Lacking revolutionary new treatment mechanisms in type 2 diabetes, pharma is relying on combinations, convenience, and beyond-the-pill services. As prices are squeezed, the winners will be those who can deliver the best-value outcomes, not necessarily those with a best-in-class drug.
A concentrated insulin formulation and extra clinical data were instrumental in Lilly’s second deal on the use of Adocia’s BioChaperone technology for an ultra-fast-acting insulin, with the latest agreement between the two companies providing funds for Adocia to pursue other insulin research areas.